Anti-PCSK 9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity – Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor – Binding Enhancement s

@inproceedings{Henne2015AntiPCSK9A,
  title={Anti-PCSK 9 Antibody Pharmacokinetics and Low-Density Lipoprotein-Cholesterol Pharmacodynamics in Nonhuman Primates Are Antigen Affinity – Dependent and Exhibit Limited Sensitivity to Neonatal Fc Receptor – Binding Enhancement s},
  author={Kirk R. Henne and Brandon L. Ason and M Lederman Howard and W. X. Wang and Jeonghoon Sun and Jared Higbee and Jie Tang and Katherine C. Matsuda and Ren Xiao Xu and Lei Zhou and Joyce Y. C. Chan and Chadwick Terence King and Derek Piper and Randal R Ketchem and Mark Leo Michaels and Simon Mark Jackson and Marc W. Retter},
  year={2015}
}
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an attractive therapeutic target for cardiovascular disease. Monoclonal antibodies (mAbs) that bind PCSK9 and prevent PCSK9:low-density lipoprotein receptor complex formation reduce serum low-density lipoprotein-cholesterol (LDL-C) in vivo. PCSK9mediated lysosomal degradation of bound mAb, however, dramatically reduces mAb exposure and limits duration of effect. Administration of high-affinity mAb1:PCSK9 complex (1:2) to mice… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 42 REFERENCES

A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2009
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Cholesterol Treatment Trialists

C Baigent, L Blackwell, +7 authors J Simes
  • (CTT) Collaboration
  • 2010
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Statins: mechanism of action and effects.

  • Journal of cellular and molecular medicine
  • 2001
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Pharmacologic target-mediated drug disposition.

  • Clinical pharmacology and therapeutics
  • 1994
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…